PF-07329640 / Pfizer - LARVOL DELTA

LTbR: A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination (clinicaltrials.gov) - P1 | N=4 | Terminated | Sponsor: Pfizer | Trial completion date: Aug 2025 ➔ Aug 2024 | Active, not recruiting ➔ Terminated; Strategic business decision

Metastases • Trial completion date • Trial termination • Colorectal Cancer • Genito-urinary Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Urothelial Cancer

LTbR: A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination (clinicaltrials.gov) - P1 | N=1 | Active, not recruiting | Sponsor: Pfizer | Recruiting ➔ Active, not recruiting | N=220 ➔ 1 | Trial completion date: Feb 2029 ➔ Aug 2025 | Trial primary completion date: Feb 2028 ➔ Aug 2024

Enrollment change • Enrollment closed • Metastases • Trial completion date • Trial primary completion date • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Urothelial Cancer

LTbR: A Study in Advanced/Metastatic Solid Tumors With the Study Medicine (PF-07329640) When Given Alone or In Combination (clinicaltrials.gov) - P1 | N=220 | Recruiting | Sponsor: Pfizer

Metastases • New P1 trial • Colorectal Cancer • Gastrointestinal Cancer • Genito-urinary Cancer • Lung Cancer • Melanoma • Non Small Cell Lung Cancer • Oncology • Solid Tumor • Urothelial Cancer